Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis

This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.

NCT Number	NCT07318129
Lead Sponsor	Glostrup University Hospital, Copenhagen Collaborators: University of Copenhagen, University of Southampton
Conditions	Relapsing Remitting Multiple Sclerosis (RRMS)
Enrollment	220 participants
Start Date	2026-01-26
Primary Completion	2028-07-15 (estimated)
Study Completion	2028-07-15 (estimated)
Updated on ClinicalTrials.gov	2026-01-28